Phil National Drug Policy l503w

PHILIPPINE NATIONAL DRUG POLICY (PNDP)

ALEJANDRO V. PINEDA, JR., MD, DFM, FPAFP

NATIONAL DRUG POLICY

The National Drug Policy(NDP) is a policy and program of the national government to ensure that safe and effective drugs are made available to all Filipinos at any time and place and at a reasonable and affordable cost.

5 PILLARS

A. Quality Assurance of Drugs

The quality assurance of safe and effective pharmaceutical products through control is a basic

 This

pillar requires the regulation

 This

is the task of the BFAD.

of the importation,manufacture, marketing, and consumer utilization of all pharmaceutical products.

B. Rational Use of Drugs by Health Professionals and Consumers

The promotion of the rational use of drugs by health professionals and consumers.

C. National Self-Sufficiency in Pharmaceuticals Development

of national self-

sufficiency in drug manufacturing

D. Rationalization of the DOH’s Procurement Program 

Designed to achieve economies of bulk purchasing and enhance the impact of DOH resources.

E. People Empowerment 

Cuts across all 4 pillars



Aims to assist people in exercising an informed choice in the purchase of cost-effective medicines.

OBJECTIVES OF THE NATIONAL DRUG POLICY

1.To assure the quality of drugs and medicines, the DOH is strengthening the capabilities of BFAD to undertake quality control, product of registration, and licensing of sales establishments.

2. To ensure the rational use of drugs by consumers and health professionals, the following are underway: a. The age of bills in Congress requiring generic labeling, prescribing, and

b. The creation of the National Drug Policy Formulary by the National Drug Committee. c. The regulation of the advertising and promotion of pharmaceutical products.

3.To achieve self-sufficiency in basic manufacturing, a fundamental plan is being developed with the participation of the United Nations Industrial Development Organization(UNIDO).

Based on this plan, private investment will be given incentives to produce raw materials and intermediate of pharmaceutical products.

4.To rationalize DOH procurement of medicines, purchases have been based on generic nomenclature.

Essential Drug List (EDL) The EDL is a concept promoted by the World Health Organization and refers to those drug which cure the vast majority of illnesses and should be affordable and available to all persons.

NATIONAL DRUG FORMULARY (NDF) 

list of medicines officially recognized and approved by the DOH.



core list of medicines considered essential and a complementary list of drugs considered useful is not essential.

GENERICS ACT OF 1988 REPUBLIC ACT NO. 6675 AN ACT TO PROMOTE, REQUIRE AND ENSURE THE PRODUCTION OF AN ADEQUATE SUPPLY, DISTRIBUTION, USE AND ACCEPTANCE OF DRUGS AND MEDICINES IDENTIFIED BY THEIR GENERIC NAMES.

GENERIC NAMES A generic name is a simpler term for the scientificallyrecognized active ingredient of a drug. Paracetamol is a medicine to control fever. Brand names of paracetamol include: Tempra, Biogesic and Tylenol.

GENERICS ACT OF 1988 STATEMENT OF POLICY

1. To promote, encourage and require the use of generic terminology in the importation, manufacture, distribution, marketing, advertising and promotion, prescription and dispensing of drugs;

STATEMENT OF POLICY

2. To ensure the adequate supply of drugs with generic names at the lowest possible cost and endeavor to make them available for free to indigent patients.

STATEMENT OF POLICY

3. To encourage the extensive use of drugs with generic names through a rational system or procurement and distribution;

STATEMENT OF POLICY

4. To emphasize the scientific basis for the use of drugs, in order that health professionals may become more aware and cognizant of their therapeutic effectiveness, and

STATEMENT OF POLICY

4. To promote drug safety by minimizing duplication medications and / or use of drugs with potentially adverse drug reactions.

PENALTY Any person who shall violate the use of generic names shall suffer the penalty graduate hereunder,vis: 1. For the first conviction, he shall suffer the penalty of reprimand which shall be officially recorded in the appropriate books of the Professional Regulation

PENALT Y 2. For the second conviction, the penalty of fine in the amount of not less than two thousand pesos(P2000) but not exceeding five thousand pesos(P5000) at the discretion of the court;

PENALTY 3. For the third conviction, the penalty of fine in the amount of not less than five thousand pesos(P5000) but not exceeding ten thousand pesos(P10,000) and suspension of his license to practice his profession for 30 days at the discretion of the court;

PENALTY 4. For the fourth and subsequent convictions, the penalty of fine not less than ten thousand pesos(P10,000) and suspension of his license to practice his profession for 1 year or longer at the discretion of the court.

PHILIPPINE NATIONAL DRUG FORMULARY ESSENTIAL DRUGS LIST Volume I, 5th Edition 2000